OPY Acquisition Corp. I
Status: Liquidated
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $126.50M |
|---|---|
| IPO Date | Oct 27, 2021 |
| CEO | Jonathan B. Siegel |
| Left Lead | Oppenheimer |
| IPO Cash in Trust | 101.0% |
| SPAC Tenor | 18 + 6 + 8 |
| IPO Sector |
Healthcare
Novel therapeutics, medical devices or services that help improve healthcare outcomes |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Oct 26, 2023 |
| Closing Date | Dec 28, 2023 |
OHAA
OHAAU
OHAAW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on OPY Acquisition Corp. I:
- Structure and cap table
- 6 directors & officers
- 13 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Jonathan B. Siegel | 48 | Chairman and Chief Executive Officer |
| Daniel E. Geffken | 64 | Chief Financial Officer |
| David R. Epstein | 60 | Director |
| Kim D. Blickenstaff | 69 | Director |
| Jonathan B. Fassberg | 55 | Director |
| Barbara L. Weber | 64 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Oppenheimer | Joint BR | 9,350,000 | units |
| Lake Street | Joint BR | 1,650,000 | |
| 11,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.